Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

Hiam Chemaitelly; Houssein H Ayoub; Sawsan AlMukdad; Peter Coyle; Patrick Tang; Hadi M Yassine; Hebah A Al-Khatib; Maria K Smatti; Mohammad R Hasan; Zaina Al-Kanaani; Einas Al-Kuwari; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F Abdul-Rahim; Gheyath K Nasrallah; Mohamed Ghaith Al-Kuwari; Adeel A Butt; Hamad Eid Al-Romaihi; Mohamed H Al-Thani; Abdullatif Al-Khal; Roberto Bertollini; Laith J Abu-Raddad

doi:10.1038/s41467-022-30895-3

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

Hiam Chemaitelly, Houssein H Ayoub, Sawsan AlMukdad, Peter Coyle, Patrick Tang, Hadi M Yassine, Hebah A Al-Khatib, Maria K Smatti, Mohammad R Hasan, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F Abdul-Rahim, Gheyath K Nasrallah, Mohamed Ghaith Al-Kuwari, Adeel A Butt, Hamad Eid Al-RomaihiMohamed H Al-Thani, Abdullatif Al-Khal, Roberto Bertollini, Laith J Abu-Raddad

Research output: Contribution to journal › Article › peer-review

156 Citations (Scopus)

45 Downloads (Pure)

Abstract

SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 vaccines against BA.1 and BA.2 infections in Qatar. BNT162b2 effectiveness was highest at 46.6% (95% CI: 33.4-57.2%) against symptomatic BA.1 and at 51.7% (95% CI: 43.2-58.9%) against symptomatic BA.2 infections in the first three months after the second dose, but declined to ~10% or below thereafter. Effectiveness rebounded to 59.9% (95% CI: 51.2-67.0%) and 43.7% (95% CI: 36.5-50.0%), respectively, in the first month after the booster dose, before declining again. Effectiveness against COVID-19 hospitalization and death was 70-80% after the second dose and >90% after the booster dose. mRNA-1273 vaccine protection showed similar patterns. mRNA vaccines provide comparable, moderate, and short-lived protection against symptomatic BA.1 and BA.2 Omicron infections, but strong and durable protection against COVID-19 hospitalization and death.

Original language	English
Article number	3082
Journal	Nature Communications
Volume	13
DOIs	https://doi.org/10.1038/s41467-022-30895-3
Publication status	Published - 02 Jun 2022

Keywords

Humans
Vaccines, Synthetic
Case-Control Studies
Qatar
COVID-19
SARS-CoV-2
COVID-19 Vaccines
mRNA Vaccines
BNT162 Vaccine
2019-nCoV Vaccine mRNA-1273

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41467-022-30895-3Licence: CC BY

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
Copyright 2022 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
Final published version, 1.68 MBLicence: CC BY

Cite this

Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., Butt, A. A., ... Abu-Raddad, L. J. (2022). Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nature Communications, 13, Article 3082. https://doi.org/10.1038/s41467-022-30895-3

@article{84822926b3de411cadb8561968a873b8,

title = "Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar",

abstract = "SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 vaccines against BA.1 and BA.2 infections in Qatar. BNT162b2 effectiveness was highest at 46.6% (95% CI: 33.4-57.2%) against symptomatic BA.1 and at 51.7% (95% CI: 43.2-58.9%) against symptomatic BA.2 infections in the first three months after the second dose, but declined to ~10% or below thereafter. Effectiveness rebounded to 59.9% (95% CI: 51.2-67.0%) and 43.7% (95% CI: 36.5-50.0%), respectively, in the first month after the booster dose, before declining again. Effectiveness against COVID-19 hospitalization and death was 70-80% after the second dose and >90% after the booster dose. mRNA-1273 vaccine protection showed similar patterns. mRNA vaccines provide comparable, moderate, and short-lived protection against symptomatic BA.1 and BA.2 Omicron infections, but strong and durable protection against COVID-19 hospitalization and death.",

keywords = "Humans, Vaccines, Synthetic, Case-Control Studies, Qatar, COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273",

author = "Hiam Chemaitelly and Ayoub, {Houssein H} and Sawsan AlMukdad and Peter Coyle and Patrick Tang and Yassine, {Hadi M} and Al-Khatib, {Hebah A} and Smatti, {Maria K} and Hasan, {Mohammad R} and Zaina Al-Kanaani and Einas Al-Kuwari and Andrew Jeremijenko and Kaleeckal, {Anvar Hassan} and Latif, {Ali Nizar} and Shaik, {Riyazuddin Mohammad} and Abdul-Rahim, {Hanan F} and Nasrallah, {Gheyath K} and Al-Kuwari, {Mohamed Ghaith} and Butt, {Adeel A} and Al-Romaihi, {Hamad Eid} and Al-Thani, {Mohamed H} and Abdullatif Al-Khal and Roberto Bertollini and Abu-Raddad, {Laith J}",

year = "2022",

month = jun,

day = "2",

doi = "10.1038/s41467-022-30895-3",

language = "English",

volume = "13",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

}

Chemaitelly, H, Ayoub, HH, AlMukdad, S, Coyle, P, Tang, P, Yassine, HM, Al-Khatib, HA, Smatti, MK, Hasan, MR, Al-Kanaani, Z, Al-Kuwari, E, Jeremijenko, A, Kaleeckal, AH, Latif, AN, Shaik, RM, Abdul-Rahim, HF, Nasrallah, GK, Al-Kuwari, MG, Butt, AA, Al-Romaihi, HE, Al-Thani, MH, Al-Khal, A, Bertollini, R & Abu-Raddad, LJ 2022, 'Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar', Nature Communications, vol. 13, 3082. https://doi.org/10.1038/s41467-022-30895-3

TY - JOUR

T1 - Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

AU - Chemaitelly, Hiam

AU - Ayoub, Houssein H

AU - AlMukdad, Sawsan

AU - Coyle, Peter

AU - Tang, Patrick

AU - Yassine, Hadi M

AU - Al-Khatib, Hebah A

AU - Smatti, Maria K

AU - Hasan, Mohammad R

AU - Al-Kanaani, Zaina

AU - Al-Kuwari, Einas

AU - Jeremijenko, Andrew

AU - Kaleeckal, Anvar Hassan

AU - Latif, Ali Nizar

AU - Shaik, Riyazuddin Mohammad

AU - Abdul-Rahim, Hanan F

AU - Nasrallah, Gheyath K

AU - Al-Kuwari, Mohamed Ghaith

AU - Butt, Adeel A

AU - Al-Romaihi, Hamad Eid

AU - Al-Thani, Mohamed H

AU - Al-Khal, Abdullatif

AU - Bertollini, Roberto

AU - Abu-Raddad, Laith J

PY - 2022/6/2

Y1 - 2022/6/2

N2 - SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 vaccines against BA.1 and BA.2 infections in Qatar. BNT162b2 effectiveness was highest at 46.6% (95% CI: 33.4-57.2%) against symptomatic BA.1 and at 51.7% (95% CI: 43.2-58.9%) against symptomatic BA.2 infections in the first three months after the second dose, but declined to ~10% or below thereafter. Effectiveness rebounded to 59.9% (95% CI: 51.2-67.0%) and 43.7% (95% CI: 36.5-50.0%), respectively, in the first month after the booster dose, before declining again. Effectiveness against COVID-19 hospitalization and death was 70-80% after the second dose and >90% after the booster dose. mRNA-1273 vaccine protection showed similar patterns. mRNA vaccines provide comparable, moderate, and short-lived protection against symptomatic BA.1 and BA.2 Omicron infections, but strong and durable protection against COVID-19 hospitalization and death.

AB - SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 vaccines against BA.1 and BA.2 infections in Qatar. BNT162b2 effectiveness was highest at 46.6% (95% CI: 33.4-57.2%) against symptomatic BA.1 and at 51.7% (95% CI: 43.2-58.9%) against symptomatic BA.2 infections in the first three months after the second dose, but declined to ~10% or below thereafter. Effectiveness rebounded to 59.9% (95% CI: 51.2-67.0%) and 43.7% (95% CI: 36.5-50.0%), respectively, in the first month after the booster dose, before declining again. Effectiveness against COVID-19 hospitalization and death was 70-80% after the second dose and >90% after the booster dose. mRNA-1273 vaccine protection showed similar patterns. mRNA vaccines provide comparable, moderate, and short-lived protection against symptomatic BA.1 and BA.2 Omicron infections, but strong and durable protection against COVID-19 hospitalization and death.

KW - Humans

KW - Vaccines, Synthetic

KW - Case-Control Studies

KW - Qatar

KW - COVID-19

KW - SARS-CoV-2

KW - COVID-19 Vaccines

KW - mRNA Vaccines

KW - BNT162 Vaccine

KW - 2019-nCoV Vaccine mRNA-1273

U2 - 10.1038/s41467-022-30895-3

DO - 10.1038/s41467-022-30895-3

M3 - Article

SN - 2041-1723

VL - 13

JO - Nature Communications

JF - Nature Communications

M1 - 3082

ER -

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this